Perrigo | PRGO - Operating Expenses


Perrigo reported $935.6M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Abbott USD 9.31B 104M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Dr.Reddys Laboratories INR 74.58B 977M Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Nestle CHF 38.42B 1.33B Dec/2025
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Reckitt Benckiser GBP 6.26B 3.51B Dec/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Xeris Pharmaceuticals USD 69.03M 1.38M Dec/2025
Zoetis USD 3.23B 1.68B Mar/2026